Stockreport

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Prese...

Savara, Inc.  (SVRA) 
Last savara, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: savarapharma.com/investors/events-presentations
PDF Mean Change From Baseline in Disease Severity Score (DSS) Showed Significant Improvement with Molgramostim Compared with Placebo at Weeks 24 and 48Responder Analysis Res [Read more]